Back to Search
Start Over
Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml.
Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml.
- Source :
-
Archives of internal medicine [Arch Intern Med] 2010 Jul 26; Vol. 170 (14), pp. 1256-61. - Publication Year :
- 2010
-
Abstract
- Background: Despite controversy over the benefit of prostate-specific antigen (PSA) screening, little is known about risk profiles and treatment patterns in men diagnosed as having prostate cancer who have a PSA value less than or equal to 4.0 ng/mL.<br />Methods: We used data from the Surveillance, Epidemiology, and End Results system to describe patient characteristics and treatment patterns in the cases of 123 934 men with newly diagnosed prostate cancer from 2004 to 2006. Age-standardized treatment rates were calculated in 5-year age strata. Logistic regression was used to quantify the odds ratios (ORs) of men with low- and high-risk disease and the use of radical prostatectomy (RP) or radiation therapy (RT).<br />Results: Men with a PSA level of 4.0 ng/mL or lower represent 14% of incident prostate cancer cases. Fifty-four percent of men diagnosed as having prostate cancer and PSA levels lower than 4.0 ng/mL harbor low-risk disease (stage, < or =T2a, PSA level, < or =10 ng/mL, and Gleason score, < or =6), but over 75% of them received RP or RT. Men with screen-detected prostate cancer and PSA values lower than 4 ng/mL were 1.49 (95% confidence interval [CI], 1.38-1.62) and 1.39 (95% CI, 1.30-1.49) times more likely to receive RP and RT, respectively, and were less likely to have high-grade disease than men who had non-screen-detected prostate cancer (OR, 0.67; 95% CI, 0.60-0.76).<br />Conclusions: Most men diagnosed as having prostate cancer with a PSA threshold below 4.0 ng/mL had low-risk disease but underwent aggressive local therapy. Lowering the biopsy threshold but retaining our inability to distinguish indolent from aggressive cancers might increase the risk of overdiagnosis and overtreatment.
- Subjects :
- Adult
Aged
Confidence Intervals
Humans
Male
Medical Records
Middle Aged
Odds Ratio
Prostatic Neoplasms diagnosis
Prostatic Neoplasms immunology
Regression Analysis
Retrospective Studies
Risk Assessment
Risk Factors
Biomarkers, Tumor blood
Prostate-Specific Antigen blood
Prostatectomy
Prostatic Neoplasms radiotherapy
Prostatic Neoplasms surgery
Subjects
Details
- Language :
- English
- ISSN :
- 1538-3679
- Volume :
- 170
- Issue :
- 14
- Database :
- MEDLINE
- Journal :
- Archives of internal medicine
- Publication Type :
- Academic Journal
- Accession number :
- 20660846
- Full Text :
- https://doi.org/10.1001/archinternmed.2010.221